Results 1 to 10 of about 892,364 (163)

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

Journal of the American College of Cardiology, 2021
BACKGROUND In cholesterol guidelines, low-density lipoprotein (LDL) cholesterol remains the primary target while apolipoprotein B (apoB) and non-high-density lipoprotein (non-HDL) cholesterol are secondary targets.
Anne Langsted, BØRge Nordestgaard, Martin Bødtker Mortensen   +2 more
exaly   +2 more sources

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

Lancet, The, 2010
Summary Background Lowering of LDL cholesterol with standard statin regimens reduces the risk of occlusive vascular events in a wide range of individuals.
J Simes, A Keech, C Reith
exaly   +2 more sources

Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study

European Heart Journal, 2021
AIMS Emerging evidence suggests that remnant cholesterol (RC) promotes atherosclerotic cardiovascular disease (ASCVD). We aimed to estimate RC-related risk beyond low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) in patients without
Sarah Nomura, Michael Tsai
exaly   +2 more sources

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.

The Lancet Diabetes and Endocrinology, 2023
INTRODUCTION Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran, which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9), results in sustained reductions in LDL cholesterol with an acceptable
K. Ray, Roel P T Troquay, F. Visseren, Lawrence A Leiter, R. Wright, S. Vikarunnessa, Zsolt Tallóczy, Xiao Zang, P. Maheux, Anastasia Lesogor, U. Landmesser   +10 more
semanticscholar   +1 more source

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels

Nature Biotechnology, 2021
Most known pathogenic point mutations in humans are C•G to T•A substitutions, which can be directly repaired by adenine base editors (ABEs). In this study, we investigated the efficacy and safety of ABEs in the livers of mice and cynomolgus macaques for ...
Tanja Rothgangl, Melissa K Dennis, Paulo J. C. Lin, Rurika Oka, D. Witzigmann, L. Villiger, W. Qi, M. Hrůzová, Lucas Kissling, Daniela Lenggenhager, Costanza Borrelli, S. Egli, Nina Frey, Noëlle Bakker, John A. Walker, A. Kadina, D. Victorov, Martin Pacesa, Susanne Kreutzer, Zacharias Kontarakis, A. Moor, M. Jinek, D. Weissman, M. Stoffel, R. van Boxtel, K. Holden, N. Pardi, B. Thöny, J. Häberle, Ying K. Tam, S. Semple, Gerald Schwank   +31 more
semanticscholar   +1 more source

Dyslipidemia and 10-year diabetes incidence in Japanese people: Population-based Panasonic cohort study 9

Frontiers in Endocrinology, 2022
Low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and LDL/HDL ratio have been associated with new-onset diabetes; however, their cut-off levels have not been determined.
Genki Kobayashi, Hiroshi Okada, Hiroshi Okada, Masahide Hamaguchi, Kazushiro Kurogi, Hiroaki Murata, Masato Ito, Michiaki Fukui   +7 more
doaj   +1 more source

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

New England Journal of Medicine, 2020
BACKGROUND Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing ...
K. Ray, R. Wright, D. Kallend, W. Koenig, Lawrence A Leiter, F. Raal, Jenna A Bisch, Tara Richardson, M. Jaros, P. Wijngaard, J. Kastelein   +10 more
semanticscholar   +1 more source

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?

American Journal of Preventive Cardiology, 2020
It remains controversial whether reductions in cardiovascular mortality after intensive lowering of low density lipoprotein cholesterol (LDL-C) depend on baseline LDL-C levels.
Safi U. Khan, Erin D. Michos
doaj   +1 more source

A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial

Nutrients, 2021
Ketogenic low-carbohydrate high-fat (LCHF) diets are popular among young, healthy, normal-weight individuals for various reasons. We aimed to investigate the effect of a ketogenic LCHF diet on low-density lipoprotein (LDL) cholesterol (primary outcome ...
J. Burén, Madelene Ericsson, N. Damasceno, Anna Sjödin   +3 more
semanticscholar   +1 more source

Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention

BMJ Open, 2022
Objective To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD).Design Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol ...
Handrean Soran, Safwaan Adam, Paul Durrington, Zohaib Iqbal   +3 more
doaj   +1 more source